TGFβ signaling regulates epithelial–mesenchymal plasticity in ovarian cancer ascites-derived spheroids
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Epithelial–mesenchymal transition (EMT) serves as a key mechanism driving tumor cell migration, invasion, and metastasis in many carcinomas. Transforming growth factor-beta (TGFβ) signaling is implicated in several steps during cancer pathogenesis and acts as a classical inducer of EMT. Since epithelial ovarian cancer (EOC) cells have the potential to switch between epithelial and mesenchymal states during metastasis, we predicted that modulation of TGFβ signaling would significantly impact EMT and the malignant potential of EOC spheroid cells. Ovarian cancer patient ascites-derived cells naturally underwent an EMT response when aggregating into spheroids, and this was reversed upon spheroid re-attachment to a substratum. CDH1/E-cadherin expression was markedly reduced in spheroids compared with adherent cells, in concert with an up-regulation of several transcriptional repressors, i.e., SNAI1/Snail, TWIST1/2, and ZEB2. Treatment of EOC spheroids with the TGFβ type I receptor inhibitor, SB-431542, potently blocked the endogenous activation of EMT in spheroids. Furthermore, treatment of spheroids with SB-431542 upon re-attachment enhanced the epithelial phenotype of dispersing cells and significantly decreased cell motility and Transwell migration. Spheroid formation was significantly compromised by exposure to SB-431542 that correlated with a reduction in cell viability particularly in combination with carboplatin treatment. Thus, our findings are the first to demonstrate that intact TGFβ signaling is required to control EMT in EOC ascites-derived cell spheroids, and it promotes the malignant characteristics of these structures. As such, we show the therapeutic potential for targeted inhibition of this pathway in ovarian cancer patients with late-stage disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · cited 1×
“The TGFb signaling pathway has been investigated for over 30 years in many human malignancies, including ovarian cancer (Massague 2008).”
BackgroundTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 1×
“TGFb signaling has been implicated in the pathogenesis of many different cancers, including EOC (Polyak & Weinberg 2009, Vergara et al. 2010).”
BackgroundTargeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · cited 1×
“Several attempts have been made in the past to test whether TGFb signaling could be targeted with inhibitors in cancer treatment (Akhurst & Hata 2012).”
BackgroundMulticellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412
Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Iwanicki, M. P., Davidowitz, R. A., Ng, M. R., Besser, A., Muranen, T., Merritt, M., Danuser, G., Ince, T., & Brugge, J. S. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0010 · Cited by 303
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253 · cited 1×
“It is well-established that this occurs through epithelial–mesenchymal transition (EMT), the mechanism believed to help tumor cells in their ability to migrate, invade and metastasize (Turley et al. 2008, Vergara et al. 2010).”
BackgroundAhmed, N., Thompson, E. W., & Quinn, M. A. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21240 · Cited by 237
Cited by
Hoarau-Véchot, J., Rafii, A., Touboul, C., & Pasquier, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010181 · Cited by 489
“More recently, TGFβ signaling has been shown to regulate EMT in spheroids derived from ovarian cancer ascites leading to the promotion of malignant properties of these structures [102].”
BackgroundYin, M., Li, X., Tan, S., Zhou, H. J., Ji, W., Bellone, S., Xu, X., Zhang, H., Santin, A. D., Lou, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87252 · Cited by 417
Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas
Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S. M., Bapat, S. A., Rangarajan, A., & Levine, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.007 · Cited by 333
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
“Transforming growth factor (TGF)-β is another marker of EMT present in ascites that is attracting interest in this area, with various investigations implicating it as a major driver of metastasis with demonstrated potential as a therapeutic target.(94,101) With a broader understanding of the mechanisms involved in the…”
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
“…with a nutator device to produce three dimensional agitation, both the hanging drop and ULA plates with agitation demonstrated higher cellular compaction, higher ECM content and increased resistance to cisplatin compared with cultures on liquid overlaid ULA plates only (Raghavan et al., 2016).”
Background
Metadata
- Authors
- Rafehi, S., Valdes, Y. R., Bertrand, M., McGee, J., Préfontaine, M., Sugimoto, A., DiMattia, G. E., & Shepherd, T. G.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2015-12-08
- Volume
- 23
- Issue
- 3
- Pages
- 147-159
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2264528830
- Cited by
- 92
- References
- 8
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TGFβ signaling regulates epithelial–mesenchymal plasticity in ovarian cancer ascites-derived spheroids. https://app.cochat.ai/papers/10.1530/erc-15-0383
- The paper
- Rafehi, S., Valdes, Y. R., Bertrand, M., McGee, J., Préfontaine, M., Sugimoto, A., DiMattia, G. E., & Shepherd, T. G. (2016). TGFβ signaling regulates epithelial–mesenchymal plasticity in ovarian cancer ascites-derived spheroids. Endocrine-Related Cancer. https://doi.org/10.1530/erc-15-0383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.